SynDiag
SynDiag is an Italian fem-tech company developing AI-powered, CE-marked medical device software for gynecological ultrasound interpretation. It sells OvAi Focus to hospitals and gynecologists and is developing OvAi X for differential diagnosis of ovarian lesions.
- Company typePrivate
- Founded2016
- HeadquartersTurin, Italy
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What SynDiag does
SynDiag s.r.l. is an Italian fem-tech company founded in 2016 as a spin-off of the Polytechnic University of Turin, developing AI-powered medical device software for gynecological ultrasound diagnostics. Its flagship product, OvAi Focus, is a CE-marked Class I medical device and is described as the world's first AI software for ultrasound data interpretation in gynecology to achieve CE marking (achieved in 2024). OvAi Focus analyzes ultrasound images and video using deep learning models validated on more than 2,000 clinical cases drawn from 12 clinical centers in Italy and abroad, providing objective anatomical descriptions, lesion characterization with false color coding, differentiation of solid and liquid areas, and computation of IOTA criteria ratios to standardize reporting. A second product, OvAi X, is in development and certification and will extend the platform into predictive risk-classification for differential diagnosis of ovarian lesions. The technology stack is built on a cloud-native, hardware-agnostic architecture compatible with major ultrasound systems, protected by six international patents covering Europe, the USA, and Asia.
The company's product ecosystem also includes Ginny Essential AI (a patient-facing protocol combining OvAi Focus with accessible reports and digital records), SynDiag Academy (CME-accredited training for gynecologists and residents), and Easy Report (patient-friendly reporting). SynDiag maintains compliance with EU MDR, EU AI Act, GDPR, ISO 13485:2016, and ISO 9001:2015, and operates a Scientific Advisory Board of 11 clinical, legal, and AI experts. The team numbers 14, including three founders — Daniele Conti (CEO), Federica Gerace (Chief AI Officer), and Rosilari Bellacosa (CTO) — along with dedicated sales, product, regulatory, clinical development, AI research, MLOps, and AI engineering functions.
Commercially, SynDiag sells to three primary segments: women/patients, gynecologists, and healthcare organizations (hospitals, clinics, IRCCS, university hospitals). The revenue model is recurring software licensing for the medical device, distributed through direct enterprise sales with a demo-first motion; pricing is not publicly disclosed. SynDiag Academy is offered free to physicians to seed adoption. The company is privately held, has not disclosed any external funding rounds, and currently operates primarily in Italy (with clinical-center partnerships in Turin, Milan, Bergamo, Bologna, Rome, and Udine) while holding IP protection internationally.
SynDiag firmographics
Firmographics- Name
- SynDiag
- Legal name
- SynDiag s.r.l.
- Website
- https://syndiag.ai
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SynDiag is an Italian fem-tech company developing AI-powered, CE-marked medical device software for gynecological ultrasound interpretation. It sells OvAi Focus to hospitals and gynecologists and is developing OvAi X for differential diagnosis of ovarian lesions.
- Ownership category
- akta.pro rank
SynDiag industry classification
Industry- Product category
- AI Medical Imaging Software
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industry
- Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ)
Keywords
Where SynDiag is headquartered
LocationHeadquarters
- HQ city
- Turin
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
SynDiag business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Software (OvAi Focus): OvAi Focus is sold as a CE-marked medical device software. The company offers demo requests for healthcare organizations and gynecologists, suggesting a sales-led model for medical facilities. The SynDiag Academy is free for training, indicating the product revenue comes from the medical device software licensing.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
SynDiag product offering
Product offeringCore offering
SynDiag develops and sells CE-marked AI-powered medical device software for gynecological ultrasound interpretation. Its flagship product, OvAi Focus, uses deep learning algorithms to provide objective and quantitative assessment of anatomical structures during transvaginal ultrasound examinations, supporting early detection of ovarian cancer. The company also offers OvAi X (advanced diagnostic support), Ginny Essential AI (patient-facing protocol), and SynDiag Academy (CME-accredited physician training).
Product overview
SynDiag is an Italian fem-tech company developing AI-powered medical devices for gynecological diagnostics, with a primary focus on early ovarian cancer detection. The product portfolio centers on OvAi Focus, the world's first CE-marked AI medical device for ultrasound interpretation, and OvAi X (in development), which expands into advanced diagnostic support for differential diagnosis. The ecosystem also includes Ginny Essential AI, a patient-facing protocol offering accessible reports and health monitoring, and SynDiag Academy, which provides CME-accredited training for healthcare professionals. All products are designed as hardware-agnostic solutions compatible with major ultrasound systems.
Differentiator
Problem solved
Functional benefit
Brands
- OvAi Focus: CE-marked AI-powered medical device software for objective and quantitative assessment of gynecological ultrasound imaging. Analyzes ultrasound images and videos to support physicians in anatomical description and lesion characterization.
- OvAi X
- Ginny Essential AI
- SynDiag Academy
- Easy Report
Products and services
- OvAi Focus CE-marked Class I medical device software that uses AI algorithms to interpret ultrasound data collected during gynecological examinations, providing collaborative support to gynecologists with objective and quantitative assessment of anatomical structures and lesion characterization (false color coding, IOTA criteria computation).
- OvAi X Advanced diagnostic support tool for differential diagnosis of ovarian lesions, currently in development and certification. Analyzes morphology and echotextures to determine risk class, supporting specialists in clinical evaluation.
- Ginny Essential AI Patient-facing diagnostic protocol combining OvAi Focus technology with Easy Report (patient-friendly medical reports), digital medical records access, and ongoing health monitoring services for women.
Quantifiable outcome
- 90% 5-year survival rate with early ovarian cancer diagnosis
- +1 more outcomes
Companies that use SynDiag
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
SynDiag technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
SynDiag partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Polytechnic University of TurincoreSynDiag originated as a spin-off from the Polytechnic University of Turin, representing the foundational academic partnership that enabled technology development. This relationship provides ongoing research collaboration and access to academic expertise in AI and medical technology.
- Italian Ministry of HealthcoreSynDiag is a manufacturer registered at the Italian Ministry of Health. The company maintains regulatory approval and operates under health authority oversight for medical device manufacturing and distribution.
- 12 Clinical Centers (Italy and abroad)coreCollaboration with 12 leading clinical centers in Italy and internationally (including IRCCS and university hospitals in Turin, Bologna, Rome, Milan, Udine) for algorithm validation, clinical research, and real-world evidence generation. These partnerships enable multicenter validation of AI technology across diverse clinical settings.
- Scientific Advisory BoardcoreTeam of 11 clinical, legal, and AI experts including gynecologists, oncologists, regulatory specialists, and data law experts. Advisors include Alice Ravizza (Regulatory Expert), Silvia Stefanelli (Digital Healthcare Law), Annamaria Ferrero (University of Turin), and others who supervise technology development to ensure clinical validity and regulatory compliance.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
SynDiag competitors and assessment
Company assessmentDirect peers
- Koios Medical: Koios Medical develops AI decision-support software for ultrasound imaging (breast, thyroid), making it the closest direct peer in AI-driven ultrasound interpretation for a specific clinical specialty.
- DiA Imaging Analysis: DiA Imaging Analysis builds AI-based software that analyzes ultrasound images (primarily cardiac), sharing SynDiag's ultrasound-AI, hardware-agnostic, clinical-decision-support positioning.
- Caption Health (GE HealthCare): Caption Health developed AI guidance and interpretation for ultrasound (now part of GE HealthCare), directly comparable as a deep-learning ultrasound AI company that reached commercial scale and acquisition.
- Ultromics: Ultromics applies AI to echocardiography ultrasound to support clinical decision-making — a comparable AI-ultrasound-for-clinicians model with regulatory clearances and NHS partnerships.
- Us2.ai: Us2.ai builds AI software for automated echocardiography analysis, closely comparable as a deep-learning ultrasound interpretation tool aimed at standardizing clinical reporting.
Broad incumbents
- Aidoc: Aidoc is a leading medical-imaging AI platform with broad hospital deployments; while it covers CT/modalities beyond ultrasound, it represents the scale of incumbent AI imaging peers SynDiag could face.
- Annalise.ai: Annalise.ai offers comprehensive AI clinical-imaging decision support across multiple anatomies, comparable as a broad medical-imaging AI competitor with regulatory clearances and enterprise sales.
- Viz.ai: Viz.ai is an established AI-powered medical imaging and care-coordination platform; relevant as a benchmark for what scaled, well-funded imaging AI companies look like in clinical workflows.
- Lunit: Lunit develops AI for medical imaging (notably mammography and pathology) with global commercialization, comparable as a publicly listed imaging-AI peer with regulatory approvals and FDA clearance.
Emerging players
- Aspira Women's Health: Aspira Women's Health focuses on ovarian cancer diagnostics (blood-based biomarker tests), addressing the same clinical indication as SynDiag but via a different (non-imaging) modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
SynDiag social profiles
Digital presenceSynDiag compliance and trust
Trust signalCompliance6 records
SynDiag financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynDiag leadership team
Management profileNumber of profiles
Profiles3 records
SynDiag funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynDiag M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynDiag
What does SynDiag do?
SynDiag develops and sells CE-marked AI-powered medical device software for gynecological ultrasound interpretation. Its flagship product, OvAi Focus, uses deep learning algorithms to provide objective and quantitative assessment of anatomical structures during transvaginal ultrasound examinations, supporting early detection of ovarian cancer. The company also offers OvAi X (advanced diagnostic support), Ginny Essential AI (patient-facing protocol), and SynDiag Academy (CME-accredited physician training).
Is SynDiag a public or private company?
SynDiag is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SynDiag founded?
SynDiag was founded in 2016. It employs 1 to 10 people.
Where is SynDiag based?
SynDiag is headquartered in Turin, Italy, in the Europe region.
How does SynDiag make money?
One revenue line is on record: medical Device Software (OvAi Focus).
Who are SynDiag's main competitors?
Direct peers on record are Koios Medical, DiA Imaging Analysis, Caption Health (GE HealthCare), Ultromics and Us2.ai. Broad incumbents are Aidoc, Annalise.ai, Viz.ai and Lunit. Aspira Women's Health is listed as an emerging player.
Does SynDiag have an API?
No public API is recorded for SynDiag.
What industry is SynDiag in?
SynDiag's product category is AI Medical Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACAMAJ, Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces. Its NAICS code is 5417 and its SIC code is 3841.